4.7 Review

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

Journal

CANCER DISCOVERY
Volume 3, Issue 1, Pages 35-43

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0361

Keywords

-

Categories

Funding

  1. PHS awards [R01CA113794, U01-1156106]
  2. Stand Up To Cancer Innovative Research Grant
  3. Program of the Entertainment Industry Foundation [SU2C-AACR-IRG0309]
  4. Cure AT/RT Now Foundation
  5. Garrett B. Smith Foundation
  6. St. Baldrick's Foundation
  7. Alex's Lemonade Stand Foundation
  8. William Lawrence and Blanche Hughes Foundation
  9. Boston Children's Hospital
  10. NATIONAL CANCER INSTITUTE [R01CA113794, U01CA105423] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Although disordered chromatin organization has long been recognized as a feature of cancer, the molecular underpinnings of chromatin structure, epigenetic regulation, and their relationships to transcription are only beginning to be understood. Cancer genome sequencing studies have revealed a novel theme: frequent mutation of epigenetic regulators. Among these, the ARID1A/BAF250A subunit of the SWI/SNF (BRG1-associated factors) chromatin remodeling complex has emerged as recurrently mutated in a broad array of tumor types. We review the genomic and functional data supporting classification of ARID1A as a tumor suppressor.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available